Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20537009 | 0.83 | HPGD (0.46) | SLC5A1SLC5A2HPGDMAPTALDH1A1 | |
| SCHEMBL3824052 | 0.82 | CA12 (0.50) | HPGDMAPTGAANPC1RAB9A | |
| SCHEMBL20554199 | 0.81 | HPGD (0.40) | HPGDMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL30541768 | 0.75 | CA12 (0.57) | MAPTNPC1RAB9ACA12CA1 | |
| SCHEMBL470906 | 0.75 | CA12 (0.57) | MAPTNPC1RAB9ACA12CA1 | |
| SCHEMBL23043017 | 0.75 | NQO2 (0.52) | NQO2TRPM4NPC1RAB9A | |
| SCHEMBL30391379 | 0.75 | NQO2 (0.52) | NQO2TRPM4NPC1RAB9A | |
| SCHEMBL28261173 | 0.75 | TRPM4 (0.63) | NQO2HPGDTRPM4MAPTALDH1A1 | |
| SCHEMBL20537236 | 0.75 | HPGD (0.47) | SLC5A1SLC5A2HPGDMAPTALDH1A1 | |
| SCHEMBL20530579 | 0.74 | NQO2 (0.50) | NQO2TRPM4CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368069-B | Oxazine compound, composition and cured product | DIC株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-108473642-B | Oxazine compound, composition and cured product | DIC株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-10913725-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10399312-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-11-22 | — | — | US | disclosed |
| EP-3401311-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3392281-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108473642-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-31 | — | — | CN | disclosed |
| CN-108368069-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-03 | — | — | CN | disclosed |
| US-4067856-A | Process for preparing polyesters with a catalyst system comprising an antimony-containing poly-condensation catalyst and an ethylenically unsaturated compound | STAUFFER CHEMICAL COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, PSMB5, CUL5 | NQO2 3031/4885SLC5A1 4090/4885SLC5A2 3815/4885 |
| US-10913725-B2 | Oxazine compound, composition and cured product | PSMB5, KDM5A, CUL5 | NQO2 2912/4885SLC5A1 4210/4885SLC5A2 3995/4885 |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | PSMB5, KDM5A, CUL5 | NQO2 2912/4885SLC5A1 4210/4885SLC5A2 3995/4885 |
| US-10399312-B2 | Oxazine compound, composition and cured product | KDM5A, PSMB5, CUL5 | NQO2 3031/4885SLC5A1 4090/4885SLC5A2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.